An official website of the United States government
          Here’s how you know
        Here’s how you know**Official websites use .gov**A
              **.gov** website belongs to an official government
              organization in the United States.
        **Secure .gov websites use HTTPS**A
              **lock** (
              Locked padlock icon) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
 Top Utility Nav
        
        
        Asian-Language Resources
        
        Portal en español


Site search Mega Menu
  

        

        Home
                  Health Topics
                                      
    
  Health Topics

    Arthritis and Rheumatic Diseases
          
    Muscle and Bone Diseases
          
    Skin Diseases
          
    All Diseases and Conditions
          
    Publication Catalog
                  Grants & Funding
                                      
    
  Grants & Funding

    Current Funding Opportunities
          
    Supported Scientific Programs
          
    NIAMS-Supported Programs
          
    Applying for a Grant
          
    NIH Policies and Guidance
          
    Peer Review and Grants Administration Resources
          
    Types of Funding Mechanisms (Activity Codes)
                  Labs @ NIAMS
                                      
    
  Labs @ NIAMS

    NIAMS Labs and Core Facilities
          
    Research Faculty
          
    Research Areas
          
    NIAMS Scientific Advances
          
    Training and Career Development
                  Clinical Trials
                                      
    
  Clinical Trials
      
            For Principal Investigators

    Clinical Trial Policies, Guidelines, and Templates
          
    Conducting Clinical Trials
          
    Register with ClinicalTrials.gov

For Patients

What is a Clinical Trial?
	Clinical Trials at NIAMS
	Clinical Trials in the Spotlight
                  News & Events
                                      
    
  Newsroom

    All NIAMS News
          
    NIAMS Newsletters
          
    Meetings & Events
                  About NIAMS
                                      
    
  About NIAMS

    Director's Page
          
    NIAMS Organization
          
    Strategic Plan Fiscal Years 2020-2024
          
    Staff Directory
          
    NIAMS Budget
          
    Partnerships
          
    Contact NIAMS
                  Community Outreach
                                      
    
  Community Outreach

    Bone Health
          
    Joint Health
          
    Muscle, Tendon, and Ligament Health
          
    Skin Health
          
    Health Information For Kids And Young Adults
          
    Health Information For Older Adults/Seniors
          
    Printable Materials for Community Events
          
    Resources in Other Languages
          
    Annual Health Observances
          
    Social Media Resources Breadcrumb
    Home
          Grants & Funding: The NIAMS Extramural Program
          Investigator-Initiated Clinical Research








Investigator-Initiated Clinical Research FacebookEmailPrintFacebookEmail     
    The NIH defines a clinical trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. Clinical trials range from small first-in-human, tolerability or exploratory studies, to larger trials of efficacy or effectiveness.Learn about NIAMS policies and procedures for investigators conducting clinical research, including short-term and long-term clinical studies.Types of Clinical Research GrantsExploratory Clinical Trial Grants (R61)This Exploratory Clinical Trials Grants Program is designed to facilitate the execution of short-term, interventional studies. Such studies must meet the NIH definition of a clinical trial and be feasible within the time and budget constraints of this Notice of Funding Opportunity (NOFO). A high priority is the use of such studies to stimulate the translation of promising research developments from laboratory, preclinical, and early human testing into clinical practice.Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01)Applicants are encouraged to propose studies that address significant obstacles or questions in the design of a clinical trial, such as determining appropriate outcome measures, or identifying when patients are most likely to respond to an intervention.NIAMS ConsultationInvestigators should contact the appropriate NIAMS Program Director prior to submitting applications for a NIAMS Exploratory Clinical Trial (R21) grant or a NIAMS Clinical Observational (R01) grant. Applicants should refer to our Consultation with NIAMS Staff for details on additional information they might wish to share with the Program Director in a pre-submission consultation.Peer Review by AMS Clinical (AMSC) Trials Review CommitteePeer review of properly completed applications submitted in response to the Program Announcements listed on this page will be conducted by the NIAMS AMS Clinical Trials Review Committee. This review committee will provide expertise in NIAMS disease areas and in clinical trial methodology.The NIAMS will make funding decisions on investigator-initiated clinical trials applications with meritorious scores based on programmatic priority. Those judged to have low program priority, or that fail to meet the criteria outlined above, will not receive funding, even if found to be scientifically sound in peer review.NIAMS Participation in other Clinical Trial Funding OpportunitiesMechanistic Clinical TrialsThe NIAMS will only accept clinical trial applications proposing mechanistic studies in response to these funding opportunities. A mechanistic study is defined as one designed to understand a behavioral or biological process, the pathophysiology of a disease, or the mechanism of action of an intervention. If a clinical trial application proposes to test a clinical outcome as its primary objective, it should be submitted to an FOA in the NIAMS Clinical Trial Suite. For more information about mechanistic studies, refer to NOT-AR-21-009.Parent R01: NIH Research Project Grant (Clinical Trial Required) PA-20-183Career DevelopmentParent K01: Mentored Research Scientist Development Award (Independent Clinical Trial Required) PA-20-176Parent K23: Mentored Patient-Oriented Research Career Development Award (Independent Clinical Trial Required) PA-20-206Parent K99/R00: NIH Pathway to Independence Award (Independent Clinical Trial Required) PA-20-187Parent K24: Midcareer Investigator Award in Patient-Oriented Research (Independent Clinical Trial Required) PA-20-193Additional Review Criteria for Career Development Award Applications Involving Clinical Trials NOT-OD-18-109**NOTE:** Applicants who propose clinical trials submitted in response to other CT Required or CT Optional funding opportunities not listed on this page will follow the guidelines and instructions in those announcements.NIH Clinical Trial Programs and ResourcesInvestigators seeking support only for drug development and who do not have access to medicinal chemistry and drug development expertise are encouraged to consider other programs for those areas which are available through individual NIH Institutes.Bridging Interventional Development Gaps (BrIDGs)Previously known as the NIH Rapid Access to Interventional Development (NIH-RAID) Program, this program offers investigators access to IND-directed services on a competitive basis. Investigators who are seeking support for such studies are encouraged to apply there.Therapeutics for Rare and Neglected Diseases (TRND)This program is designed to support pre-clinical development of therapeutic candidates intended to treat rare or neglected disorders, with the goal of enabling an Investigational New Drug (IND) application. TRND stimulates drug discovery and development research collaborations among NIH and academic scientists, nonprofit organizations, and pharmaceutical and biotechnology companies working on rare and neglected illnesses. Investigators are encouraged to refer to NCATS TRND to determine if there are opportunities offered through this program that suits their needs.Trial Innovation NetworkThis program is designed to address critical roadblocks in clinical trials and to accelerate the translation of novel interventions into life-saving therapies. The network will focus on operational innovation, operational excellence and collaboration while leveraging the expertise, diversity and broad reach of the NCATS CTSA Program.


Last Updated: November 2023


Back to Top
 About NIAMS
                    Clinical Trials
                    Grants & Funding
                    Health Topics
                    Labs @ NIAMS
              News Room
                    NIAMS Multimedia Library
                    Disclaimer
                    FOIA
                    Contact us
              Privacy Statement
                    Accessibility
                    HHS Vulnerability Disclosure
                    Social Media Moderation Policy
                    NIAMS Archives
        Subscribe to Our E-Newsletters
            Click the button to see different options to sign up for newsletters.
            Click Here to Subscribe
          Follow us on
  
  About NIH
                  Accessibility Support
            FOIA requests
                  No FEAR Act data
            Office of the Inspector General
                  Performance reports
            Privacy Policy